Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients
Treatment with the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide results in a greater decrease in liver fat content (LFC) relative to the GLP-1 receptor agonist semaglutide in patients with nonalcoholic fatty liver disease (NAFLD), results of a phase IIa trial have shown.
Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients
03 Oct 2023
Response to nucleos(t)ide analogues for hepatitis B higher among men vs women
Treatment outcomes with nucleos(t)ide analogues for hepatitis B patients appear to differ by sex, such that men are more likely to have biochemical response and achieve clinical remission than women, a study has shown.
Response to nucleos(t)ide analogues for hepatitis B higher among men vs women
25 Sep 2023
Liver transplant confers better long-term survival in select CRC patients
In the treatment of patients with nonresectable colorectal cancer (CRC) with liver metastases, liver transplantation may improve long-term survival outcomes especially when performed for those with favourable prognostic scoring, according to a study.
Liver transplant confers better long-term survival in select CRC patients
19 Sep 2023
Bulevirtide boasts high barrier to resistance for chronic hepatitis delta
A recent study has found no amino acid substitutions associated with reduced sensitivity to bulevirtide (BLV) monotherapy, a hepatitis D/B virus (HDV/HBV) entry inhibitor, at baseline or week 24 in patients with virologic breakthrough after BLV treatment.